Theratechnologies Inc. (TH) Price Target Lowered to C$8.75 at National Bank Financial
Theratechnologies Inc. (TSE:TH) had its target price cut by analysts at National Bank Financial from C$9.75 to C$8.75 in a research report issued on Tuesday. The brokerage presently has an “outperform” rating on the stock. National Bank Financial’s price objective points to a potential upside of 19.37% from the company’s current price.
Separately, Scotiabank cut their target price on Theratechnologies from C$9.50 to C$9.25 and set an “outperform” rating on the stock in a report on Friday, September 29th.
Shares of Theratechnologies (TSE TH) traded down C$0.17 on Tuesday, hitting C$7.33. The company had a trading volume of 78,814 shares, compared to its average volume of 152,934. Theratechnologies has a 12 month low of C$2.61 and a 12 month high of C$8.72.
Theratechnologies Company Profile
Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.